Case Report

Crescentic Glomerulonephritis and Membranous Nephropathy: A Rare Overlap

Mohamedanwar Ghandour,1 Heba Osman,2 Samer Alkassis,3 Alix Charles,3 Kristina Zalewski,3 Jarrett Weinberger,3 Yahya Malik-Osman,1 and Zeenat Y. Bhat1

1Department of Internal Medicine WSU SOM, Division of Nephrology Wayne State University, Detroit, MI, USA
2Department of Internal Medicine/Pediatrics, Wayne State University/Detroit Medical Center, Detroit, MI, USA
3Department of Internal Medicine WSU SOM, Wayne State University, Detroit, MI, USA

Correspondence should be addressed to Mohamedanwar Ghandour; ha4202@wayne.edu

Received 28 September 2021; Accepted 25 May 2022; Published 24 June 2022

Academic Editor: Hernán Trimarchi

Copyright © 2022 Mohamedanwar Ghandour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Membranous nephropathy (MN) is a disease that affects the basement membrane of the glomeruli of the kidney resulting in proteinuria. The concurrent incidence of vasculitic glomerulonephritis and MN in the same patient is unusual. Herein, we report a case with this unusual combination. Case. Our patient is a 53-year-old Hispanic male with a medical history of tobacco use, type 2 diabetes mellitus, and hypertension who presented with hematuria and was found to have nephrotic range proteinuria and renal impairment. Blood workup revealed positive ANCA serology, which led to a renal biopsy that showed crescentic vasculitis in addition to membranous nephropathy. The patient was started on intermittent hemodialysis (HD) and treated initially with intravenous (IV) pulse steroids; subsequently, oral prednisolone and IV cyclophosphamide were initiated. The patient remained HD dependent at the time of discharge with the resolution of hematuria. A follow-up with an outpatient nephrology clinic was arranged. Conclusion. Membranous nephropathy complicated by crescentic glomerulonephritis has a more aggressive clinical course and decline in renal function compared to MN alone which can lead to initiating renal replacement therapy. However, immunosuppressive drugs can result in significant improvement of renal function if started early enough.

1. Introduction

Membranous nephropathy (MN) is a common etiology of nephrotic syndrome, especially in on-diabetic adults. Histologically, it is characterized by a light microscopy pattern of basement membrane thickening with deposition of immunoglobulins and complement proteins [1]. MN can be either idiopathic or associated with an underlying disease such as systemic lupus nephritis, other autoimmune disorders, malignancies, or drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) [2–4]. On the other hand, antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of chronic inflammatory diseases affecting small and medium-sized vessels. Literature reports rare cases of vasculitic or crescentic glomerulonephritis in membranous nephropathy, except in those cases associated with systemic lupus erythematosus [5, 6]. Herein, we report a rare case of crescentic glomerulonephritis with membranous nephropathy. To our knowledge, the immunopathogenesis of this uncommon overlap of membranous nephropathy and crescentic glomerulonephritis is limited.

1.1. Case Presentation. Our patient is a 53-year-old Hispanic male with a medical history of tobacco use, type 2 diabetes mellitus, and HTN who presented to the emergency department with hematuria and diarrhea for 4 days. He additionally complained of symptoms of chronic sinusitis and epistaxis that occurred all year round. His medications at home included tramadol, celecoxib, glipizide, metformin, lisinopril, and metoprolol. Physical examination was only remarkable for 1+ pitting edema in his lower extremities bilaterally and dental caries. There were no signs of
photosensitivity, malar rash, oral ulcers, lymphadenopathy, pericarditis, or sinus involvement. On admission, the patient was found to have a creatinine of 8.04 mg/dL (reference range 0.70–1.3 mg/dL). His baseline creatinine was 0.9 mg/dL less than eight months ago. His urinalysis revealed gross and microscopic hematuria, with RBC >100/HPF, 3+ protein, and no casts. A CT abdomen/pelvis was performed on admission which was unremarkable for any signs of obstruction; however, it revealed fibrotic changes in the lower lung bases. The urine protein creatinine ratio (UPCR) was 19.2 g/mg and low serum albumin was 2.7 gm/dL (reference range 3.5–5.7 gm/dL). ANCA antibody was positive; however, all viral markers (hepatitis B, C, syphilis EIA, and HIV), complement C3 and C4 levels, and autoimmune antibody profiles (ANA, rheumatoid factor, anti-ds DNA antibody, and antiglomerular basement membrane antibody) were all negative or within normal limits. The patient had high titers of myeloperoxidase (MPO) antibody. All other infectious workups such as urine culture and blood cultures were negative. CT of the lungs revealed interval worsening of fibrotic changes with honeycombing predominantly in the lung bases, suggesting usual interstitial pneumonia. Pulmonology was consulted and reported this was consistent with ANCA-associated lung involvement. Renal ultrasound showed normal kidney size with no hydronephrosis.

Renal biopsy was then performed which revealed membranous pattern glomerulonephritis with diffuse cellular crescents. There was moderate interstitial fibrosis, tubular atrophy with focal segmental fibrinoid necrosis (Figure 1). Light microscopy revealed 50% of sampled glomeruli had active cellular crescents (Figure 2). Immunohistochemical staining for phospholipase A2 receptor (PLA2R), thrombospondin type 1 domain-containing 7A (THSD7A), and neural epidermal growth factor-like 1 were negative. Immunofluorescence revealed granular capillary wall and mesangial staining for IgA (3+) and IgG (3+) (Figures 3 and 4). All the other stains were negative. Electron microscopy revealed extracapillary hypercellularity and segmental thickening in the glomerular capillary basement membranes with severe effacement of podocyte foot processes. There was no significant mesangial hypercellularity. Global subepithelial immune-type electron-dense deposits were identified, consistent with a membranous pattern with occasional intramembranous deposits.

Throughout his stay, the patient’s creatinine continued to rise for which intermittent hemodialysis was initiated. The patient was also started on pulse dose steroids followed by maintenance steroids and intravenous cyclophosphamide. The patient reported a resolution of hematuria after the
| Title/authors                                                                                                                                                                                                 | Patient (age/sex) | PLA2R | ANCA by IF | ANCA specificity by ELISA | Treatment                                                                 | Prognosis                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------|------------|--------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Membranous nephropathy with proteinase 3-ANCA-associated vasculitis successfully treated with rituximab; Shun Yoshida, Shunichiro Hanai, Daiki Nakagomi, Kei Kobayashi, Kazuya Takahashi, Fumihiko Furuya [7] | 73/F             | PR3   |            |                          | Oral prednisolone and IV rituximab                                        | Renal function immediately improved, along with symptoms and urinalysis abnormalities                 |
| Association of vasculitis glomerulonephritis with membranous nephropathy: A report of 10 cases; Tse WY, Howie AJ, Adu D, Savage CO, Richards NT, Wheeler DC, Michael J [1]                                          | 10 patients: 9 males/1 female, 30–70 years |       |            |                          | Oral prednisolone and cyclophosphamide                                    | Renal function improved in 3 patients; 2 patients required RRT; 3 patients died: one of systemic vasculitis and 2 of sepsis |
|                                                                                             | 30/M             | C-ANCA|            |                          | Oral prednisolone and cyclophosphamide                                    | Stable renal function. Complication: squamous lung CA 10 years after presentation                      |
|                                                                                             | 39/M             | Negative|          |                          | Oral prednisolone and cyclophosphamide                                    | Recovery. Complication: steroid-induced DM. Duration of follow-up: 7 months                          |
|                                                                                             | 41/M             | Negative|          |                          | Oral prednisolone and cyclophosphamide                                    | Stable renal function, duration of follow-up: 3 years                                              |
|                                                                                             | 58/F             | Negative|          |                          | Oral prednisolone and cyclophosphamide                                    | Dialysis, duration of follow-up: 7 years                                                          |
|                                                                                             | 63/M             | NA     |            |                          | Oral prednisolone and azathioprine for 3 years, followed by prednisolone and cyclophosphamide | Death, duration of follow-up: 6 years                                                              |
|                                                                                             | 64/M             | P-ANCA |            |                          | Oral prednisolone and azathioprine for 3 years, followed by prednisolone and cyclophosphamide | Dialysis, duration of follow-up: 2 years                                                          |
|                                                                                             | 65/M             | P-ANCA |            |                          | Oral prednisolone and cyclophosphamide                                    | Death (after 4 months)                                                                                |
|                                                                                             | 66/M             | Negative|          |                          | Oral prednisolone and cyclophosphamide                                    | Death (after 2 months)                                                                               |
|                                                                                             | 70/M             | C-ANCA |            |                          | Oral prednisolone, cyclophosphamide, and plasma exchange                  | Recovery (duration of follow-up:4 years)                                                            |
| Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis; Samih H. Naar, Samar M. Said, Anthony M. Valeri, Michael B. Stokes, Naveed N. Masani, Vivette D. D’Agati, and Glen S. Markowitz [4] | 64/M             | C-ANCA | NA         | Prednisone and cyclophosphamide                                           | Resolution of pulmonary lesions, normalization of Cr, diminution of proteinuria                     |
|                                                                                             | 68/F             | NA     | MPO        | Prednisone and cyclophosphamide                                           | Normalization of Cr                                                                                   |
| Anti-neutrophil cytoplasmic antibody-positive eosinophilic granulomatosis with polyangiitis; Yuexin Zhu, Qing Chang, Xiangyan Gao, Song Zheng, Peiling Li, Junjun Luan, Hua Zhou [8] | 47/F             | P-ANCA | MPO        | Methylprednisolone and then prednisone and cyclophosphamide               | Diminution of proteinuria and disappearance of crescents (on repeat bx)                               |
| Anti-neutrophil cytoplasmic antibody-positive eosinophilic granulomatosis with polyangiitis can it cause membranous nephropathy? S B Mahmood, H Ahmad, I Wu, D Haselby, M M LeClaire, R Naar [9] | 47/F             | P-ANCA | MPO        | Prednisone and cyclophosphamide                                           | Normalization of Cr                                                                                   |
|                                                                                             | 63/F             | P-ANCA | MPO        | Prednisone and cyclophosphamide                                           | Partial recovery                                                                                     |
| Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis; Yuexin Zhu, Qing Chang, Xiangyan Gao, Song Zheng, Peiling Li, Junjun Luan, Hua Zhou [8] | ??               | PLA2R positive| ANCA positive | Prednisone and cyclophosphamide                                           | Recovery                                                                                             |
| Anti-neutrophil cytoplasmic antibody-positive eosinophilic granulomatosis with polyangiitis can it cause membranous nephropathy? S B Mahmood, H Ahmad, I Wu, D Haselby, M M LeClaire, R Naar [9] | 63/F             | P-ANCA | MPO        | Rituximab                                                               | Recovery                                                                                             |
Table 1: Continued.

| Title/authors                                                                 | Patient (age/sex) | PLA2R       | ANCA by IF | ANCA specificity by ELISA | Treatment                                                   | Prognosis                                      |
|------------------------------------------------------------------------------|-------------------|-------------|------------|----------------------------|------------------------------------------------------------|-----------------------------------------------|
| Primary membranous nephropathy presenting with crescentic glomerulonephritis 25 years after initial presentation: A case report; David Massicotte-Azarniouch, Sean Barbour, Paula Blanco, Edward G Clark [10] | 63/M              | PLA2R positive | Negative  | ANCA Negative               | Prednisone and cyclophosphamide and then azathioprine for maintenance | Dialysis and then partial recovery             |
| Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy lesions: report of two patients with microscopic polyangiitis; Tominaga K, Uchida T; Imakure T et al. [11] | 52/M              | PLA2R positive | Not reported | MPO Not reported | Not reported                                         | Not reported                                  |
| Crescetnc glomerulonephritis and membranous nephropathy: A rare coexistence; Olga Balafa, Rigas Kalaitzidis, Georgios Liapis, Sofia Xiromeriti, Fotios Zarzoulas, Georgios Baltatzis and Moses Elisaf [5] | 63/F              | PLA2R positive | Not reported | MPO Not reported | Not reported                                         | Not reported                                  |
| 27 patients with ANCA-GN and characteristics of MN on renal biopsy           | 58/M              | p-ANCA      |            |                             | Prednisolone, cyclophosphamide, and plasmapheresis         | Recovery, duration of follow-up: 3 months       |
| 17 M and 10 F, with an age of 52.4 ± 17.7 years                              |                   |             |            |                             | Prednisone and cyclophosphamide                           |                                               |
| 25 p-ANCA positive; 2 c-ANCA positive                                       |                   |             |            |                             | 11 of 27 (40.7%) died; 13 of 27 (48.1%) progressed to ESRD |                                               |
| Clinical and immunologic characteristics of patients with ANCA-associated glomerulonephritis combined with membranous nephropathy a retrospective cohort study in a single Chinese center; Zou, Rong; Liu, Gang; Cui, Zhao; Chen, Min; Zhao, Ming Hui [12] | 17 M and 10 F, with an age of 52.4 ± 17.7 years |             |            |                             | ANCA-GN patients with MN had significantly poorer renal outcome ($P = 0.021$) and patients' survivals ($P = 0.036$) compared with the patients without MN. No significant difference in causes of death between ANCA-GN patients with and without MN. Infection is the first cause of death in ANCA-GN patients with and without MN |                                               |
| Title/authors | Patient (age/sex) | PLA2R | ANCA by IF | ANCA specificity by ELISA | Treatment | Prognosis |
|--------------|------------------|-------|------------|---------------------------|-----------|-----------|
| Membranous nephropathy with crescents: A series of 19 cases; Erika F. Rodriguez, Samih H. Nasr, Christopher P. Larsen, Sanjeev Sethi, Mary E. Fidler, Lynn D. Cornell [13] | 19 patients with ANCA and crescentic MN No patient had positive anti-dsDNA, hep B and C, or HIV | 38% PLA2R positive | All negative | All negative | Prednisone and cyclophosphamide and then cyclosporine | Recovery, duration of follow-up: 138 months |
| | 22/M | Negative | Negative | Prednisone and cyclophosphamide | Partial recovery, duration of follow-up: 26 months |
| | 76/F | Negative | Negative | Prednisone and cyclophosphamide | Recovery, duration of follow-up: 6 months |
| | 80/F | Negative | Negative | Mycophenolate mofetil and prednisone | ESRD, duration of follow-up: 1.5 months |
| | 69/F | Negative | Negative | Prednisone, Prednisone and cyclophosphamide orally with remission; then azathioprine; then prednisone and cyclophosphamide | Duration of follow-up: 56 months |
| | 57/M | Negative | Negative | Prednisone and cyclophosphamide | Worsening renal function, duration of follow-up: 5 months |
| | 41/M | Negative | Negative | None | ESRD, duration of follow-up: 35 months |
| | 20/F | Negative | Negative | Enalapril | Recovery, duration of follow-up: 3 months |
| | 17/F | Negative | Negative | Prednisone, cyclophosphamide, and mycophenolate | Partial recovery, duration of follow-up: 16 months |
| | 50/M | Negative | Negative | Prednisone and cyclophosphamide (no response at 6 m); then, prednisone and cyclosporine; then, prednisone and tacrolimus | Recovery, duration of follow-up: 32 months |
| | 5/F | Negative | Negative | Prednisone | Partial recovery, duration of follow-up: 11 months |
| | 86/M | Negative | Negative | Prednisone and cyclophosphamide | Worsening renal function, duration of follow-up: 2 months |
| | 64/M | Negative | Negative | Prednisone and cyclophosphamide | Partial recovery, duration of follow-up: 27 months |
| | 72/F | Negative | Negative | Prednisone and cyclophosphamide | Partial recovery, duration of follow-up: 19 months |
| | 62/M | Negative | Negative | Unknown | ESRD, duration of follow-up: 11 months |
| | 64/M | Negative | Negative | Prednisone and cyclophosphamide (no response at 2 m); then 4 doses rituximab; then mycophenolate and prednisone (no response) | Partial recovery, duration of follow-up: 11 months |
| | 72/M | Negative | Negative | Losartan | Partial recovery, duration of follow-up: 9 months |
| | 58/M | Negative | Negative | Prednisone and cyclophosphamide orally for 2 m; then azathioprine for 1 y | Partial recovery, duration of follow-up: 11 months |
| | 70/F | Negative | Negative | Unknown | Dialysis within 1 month |
| | 56/M | Negative | Negative | Prednisone and cyclophosphamide | Partial recovery, duration of follow-up: 3 months |
| Title/authors                                                                 | Patient (age/sex) | PLA2R | ANCA by IF | ANCA specificity by ELISA | Treatment                              | Prognosis          |
|------------------------------------------------------------------------------|-------------------|-------|------------|---------------------------|----------------------------------------|--------------------|
| A case of membranous glomerulonephritis with superimposed anti-neutrophil cytoplasmic antibody-associated rapidly progressive crescentic glomerulonephritis; Yoo Hyung Kim, Hae Ri Kim, Young Rok Ham, Jae Woong Jeon, Sarah Chung, Dae Eun Choi, Kang Wook Lee and Ki Ryang Na [14] | 65/M              | Not reported | p-ANCA | MPO | Methylprednisolone and cyclophosphamide | ESRD               |
| Membranous glomerulonephritis with superimposed ANCA-associated vasculitis: Another case report; Antonio Granata, Fulvio Floccari [15] | 67/M              | Not reported | p-ANCA | Not reported | Methylprednisolone and cyclophosphamide | Partial recovery   |

Table 1: Continued.
initiation of steroids; however, patient remained dialysis-dependent. The patient was discharged in a stable condition and scheduled for follow-up with the outpatient nephrology clinic.

2. Discussion

The primary antibodies identified in AAV are proteinase 3 (PR3) and myeloperoxidase (MPO)-ANCA antibodies. These autoantibodies are hallmarks of AAV, with PR3-ANCA being the most common in GPA, while MPO-ANCA is the most common in MPA. However, the association of vasculitic glomerulonephritis with membranous nephropathy is rare, estimated to be <5% of all membranous glomerulonephritis (MGN) cases, and is reported only in a handful of times in the literature [1]. Many concomitant MGN and AAV cases are also diagnosed together at presentation (Table 1). Our case had positive myeloperoxidase (MPO)-ANCA antibodies. The histological pattern of MGN is characterized by the formation of subepithelial immune complex deposits with changes to the glomerular basement membrane. Primary MGN occurs in approximately 75% of MGN cases and is caused by circulating anti-PLA2R antibodies against the podocyte antigens. In 25% of cases, secondary MGN occurs and is associated with hepatitis B, autoimmune diseases, thyroiditis, malignancies, and certain drug use such as nonsteroidal anti-inflammatory drugs (NSAIDs) [2].

Microscopic hematuria, proteinuria, and acute kidney failure are all common presentations of MGN associated with ANCA vasculitis [3, 4]. In a case series of 15 patients reported by Nikolopoulou et al., microscopic hematuria was detected in all of them except for one who was anuric. Moreover, proteinuria was also noticed with a median UPCR of 819.5 mg/mmol (reference range 88–5600) [3]. The reported case presented with UPCR of 19.2 g/day. Extrarenal symptoms are also common including fatigue, arthralgias, and malaise. A literature review done by Balafa et al., which included 38 patients with ANCA-positive MGN and 30 patients with ANCA-negative MGN, revealed that vasculitis symptoms predominated in the first group, but were absent in the second one [5].

The renal function at presentation along with the presence of antibodies may predict the clinical outcome. However, prognosis is variable with 40% of patients progressing to end-stage renal disease [3]. Patients with MGN and ANCA-associated NCGN are likely to have heavier proteinuria and a worse prognosis than patients with ANCA-associated NCGN alone [4]. In addition to higher levels of urinary protein excretion and decreased eGFR at the time of renal biopsy being risk factors for poor prognosis in MGN, crescent formation was reported to be another risk factor for worse renal outcome [6].

Prompt aggressive treatment can lead to stabilization of renal function and a significant decline in proteinuria. Treatment typically involves a combination of immunosuppressive agents such as steroids and cyclophosphamide and/or rituximab. Nasr et al.’s case series of 14 patients revealed that 5 out of 14 patients progressed to ESRD despite treatment; however, ANCA testing was repeated after treatment in 7 patients and revealed that 5 patients were seronegative [3]. In Nikolopoulou et al.’s case series, 9 patients had stabilization or improvement of renal function, 6 had progressed to ESRD, and 4 died in the median 72-month follow-up period [4]. All the patients were treated with steroids, 10 with cyclophosphamide and 6 with rituximab [4]. There is currently not enough evidence to guide treatment when deciding between the addition of cyclophosphamide versus rituximab.

3. Conclusion

Our case of a 53-year-old man who was found to have both ANCA-associated GN and MGN with kidney biopsy represents a rare dual glomerulopathy. An overlap between MN and ANCA is rare and might require a histological diagnosis. Presentation with proteinuria, microscopic hematuria, and acute kidney injury should prompt treatment for rapidly progressive glomerulonephritis to prevent poor clinical outcomes and progression to end-stage renal disease.

Disclosure

The abstract was presented at the American Society of Nephrology.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] W. Tse, A. Howie, D. Adu et al., “Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases,” Nephrology Dialysis Transplantation, vol. 12, no. 5, pp. 1017–1027, 1997.
[2] A. B. Fogo, M. A. Lusco, B. Najafian, and C. E. Alpers, “AJKD atlas of renal pathology: membranous nephropathy,” American Journal of Kidney Diseases, vol. 66, no. 3, pp. e15–e17, 2015.
[3] A. Nikolopoulou, I. Huang-Doran, S. P. McAdoo, M. E. Griffith, H. T. Cook, and C. D. Pusey, “Membranous glomerulonephritis with crescents,” Kidney International Reports, vol. 4, no. 11, pp. 1577–1584, 2019.
[4] S. H. Nasr, S. M. Said, A. M. Valeri et al., “Membranous glomerulonephritis with ANCA--associated necroizing and crescentic glomerulonephritis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 299–308, 2009.
[5] O. Balafa, R. Kalaitzidis, G. Liapis et al., “Crescentic glomerulonephritis and membranous nephropathy: a rare coexistence,” International Urology and Nephrology, vol. 47, no. 8, pp. 1373–1377, 2015.
[6] J. Wang, P. Zhu, Z. Cui et al., “Clinical features and outcomes in patients with membranous nephropathy and crescent formation,” Medicine (Baltimore), vol. 94, no. 50, Article ID e2294, 2015.
[7] S. Yoshida, S. Hanai, D. Nakagomi, K. Kobayashi, K. Takahashi, and F. Furuya, “Membranous nephropathy with proteinase 3-ANCA-associated vasculitis successfully treated
with rituximab,” Internal Medicine, vol. 60, no. 1, pp. 145–150, 2021.

[8] Y. Zhu, Q. Chang, X. Cao et al., “Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis,” Clinical Nephrology, vol. 92, no. 4, pp. 208–215, 2019.

[9] S. Mahmoud, H. Ahmad, J. Wu, D. Haselby, M. LeClaire, and R. Nasr, “Anti-neutrophil cytoplasmic antibody-positive eosinophilic granulomatosis with polyangiitis: can it cause membranous nephropathy?” Scandinavian Journal of Rheumatology, vol. 48, no. 3, pp. 256-257, 2019.

[10] D. Massicotte-Azarniouch, S. Barbour, P. Blanco, and E. G. Clark, "Primary membranous nephropathy presenting with crescentic glomerulonephritis 25 years after initial presentation: a case report,” Clinical Nephrology, vol. 90, no. 4, pp. 291–295, 2018.

[11] K. Tominaga, T. Uchida, T. Imakiire et al., “Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis,” BMC Nephrology, vol. 19, pp. 120–125, 2018.

[12] R. Zou, G. Liu, Z. Cui, M. Chen, and M. H. Zhao, "Clinical and immunologic characteristics of patients with ANCA-associated glomerulonephritis combined with membranous nephropathy: a retrospective cohort study in a single Chinese center," Medicine (Baltimore), vol. 94, no. 37, Article ID e1472, 2015.

[13] E. F. Rodriguez, S. H. Nasr, C. P. Larsen, S. Sethi, M. E. Fidler, and L. D. Cornell, "Membranous nephropathy with crescents: a series of 19 cases,” American Journal of Kidney Diseases, vol. 64, no. 1, pp. 66–73, 2014.

[14] Y. H. Kim, H. R. Kim, Y. R. Ham et al., "A case of membranous glomerulonephritis with superimposed anti-neutrophil cytoplasmic antibody-associated rapidly progressive crescentic glomerulonephritis,” Chonnam Medical Journal, vol. 51, no. 2, pp. 102–105, 2015.

[15] A. Granata and F. Floccari, "Membranous glomerulonephritis with superimposed ANCA-associated vasculitis: another case report,” Clinical Kidney Journal, vol. 4, no. 1, pp. 80–81, 2011.